Genmab A/S
Close on Nov 20, 2026
Genmab A/S Total Contract Liabilities by Year
Total Contract Liabilities (Deferred Collaboration Revenue) ($M)
Genmab A/S Total Contract Liabilities: $119M in FY2025, up 70.0% from a year earlier.
Where the FY2025 figure comes from
“|| Total | 119 | 70 | 76”
Source: Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗
Upfront and milestone payments from AbbVie and Gilead (assumed via Merus) deferred pending satisfaction of R&D performance obligations.
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Contract Liabilities (Deferred Collaboration Revenue) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 119 | +70.0% | Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗ |
| FY2024 | Dec 31, 2024 | 70 | -7.9% | Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗ |
| FY2023 | Dec 31, 2023 | 76 | – | Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗ |
Breakdown
What makes up total Contract Liabilities
Cite this data
StockData. (2026). Genmab A/S Total Contract Liabilities ($M), annual FY2023–FY2025 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/contract-liabilities-total
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?